Is Iron Chelation Important in Preventing Glycation of Bovine Serum Albumin in Vitro?

References

1. Nagai, R., Murray, D.B., Metz, T.O. and Baynes, J.W. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 61 (2012) 549-559.Suche in Google Scholar

2. Frizzell, N. and Baynes, J.W. Chelation therapy for the management of diabetic complications: a hypothesis and a proposal for clinical laboratory assessment of metal ion homeostasis in plasma. Clin. Chem. Lab. Med. 52 (2014) 69-75.Suche in Google Scholar

3. Price, D.L., Rhett, P.M., Thorpe, S.R. and Baynes, J.W. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276 (2001) 48967-48972.Suche in Google Scholar

4. Sadowska-Bartosz, I., Galiniak, S. and Bartosz, G. Kinetics of glycoxidation of bovine serum albumin by methylglyoxal and glyoxal and its prevention by various compounds. Molecules 19 (2014) 4880-4896.Suche in Google Scholar

5. Sadowska-Bartosz, I., Galiniak, S. and Bartosz, G. Kinetics of glycoxidation of bovine serum albumin by glucose, fructose and ribose and its prevention by food components. Molecules 19 (2014) 18828-18849.Suche in Google Scholar

6. Sadowska-Bartosz, I., Adamczyk-Sowa, M., Galiniak, S., Mucha, S., Pierzchala, K. and Bartosz, G. Oxidative modification of serum proteins in multiple sclerosis. Neurochem. Int. 63 (2013) 507-516.Suche in Google Scholar

7. Dinis, T.C., Maderia, V.M. and Almeida, L.M. Action of phenolic derivatives (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers. Arch. Biochem. Biophys. 315 (1994) 161-169.Suche in Google Scholar

8. Sadowska-Bartosz, I., Galiniak, S., Skolimowski, J., Stefaniuk, I. and Bartosz, G. Nitroxides prevent protein glycoxidation in vitro. Free Radic. Res. 26 (2014) 1-9.Suche in Google Scholar

9. Raghav, A., and Ahmad, J. Glycated serum albumin: a potential disease marker and an intermediate index of diabetes control. Diabetes Metab. Syndr. 8 (2014) 245-251.Suche in Google Scholar

10. Arasteh, A., Farahi, S., Habibi-Rezaeim M. and Moosavi-Movahedi, A.A. Glycated albumin: an overview of the in vitro models of an in vivo potential disease marker. J. Diabetes Metab. Disord. 13 (2014) DOI: 10.1186/2251-6581-13-49.10.1186/2251-6581-13-49Suche in Google Scholar PubMed PubMed Central

11. Koga, M. Glycated albumin; clinical usefulness. Clin. Chim. Acta 433 (2014) 96-104.10.1016/j.cca.2014.03.001Suche in Google Scholar PubMed

12. Argirova, M.D. and Ortwerth, B.J. Activation of protein-bound copper ions during early glycation: study on two proteins. Arch. Biochem. Biophys. 420 (2003) 176-184.10.1016/j.abb.2003.09.005Suche in Google Scholar PubMed

13. Hamada, Y., Nakashima, E., Naruse, K., Nakae, M., Naiki, M., Fujisawa, H., Oiso, Y., Hotta, N. and Nakamura, J. A copper chelating agent suppresses carbonyl stress in diabetic rat lenses. J. Diabetes Complications 19 (2005) 328-334.Suche in Google Scholar

14. Cooper, G.J. Selective divalent copper chelation for the treatment of diabetes mellitus. Curr. Med. Chem. 19 (2012) 2828-2860.Suche in Google Scholar

15. Hunt, J.V. and Wolff, S.P. Oxidative glycation and free radical production: a causal mechanism of diabetic complications. Free Radic. Res. Commun. 12-13 (1991) 115-123.Suche in Google Scholar

16. Smith, P.R. and Thornalley, P.J. Mechanism of the degradation of nonenzymatically glycated proteins under physiological conditions. Studies with the model fructosamine, N epsilon-(1-deoxy-D-fructos-1-yl)hippuryl-lysine. Eur. J. Biochem. 210 (1992) 729-739.Suche in Google Scholar

17. Nakamura, J., Hamada, Y., Chaya, S., Nakashima, E., Naruse, K., Kato, K., Yasuda, Y., Kamiya, H., Sakakibara, F., Koh, N. and Hotta, N. Transition metals and polyol pathway in the development of diabetic neuropathy in rats. Diabetes Metab. Res. Rev. 18 (2002) 395-402. Suche in Google Scholar

18. Baynes, J.W. and Murray, D.B. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. Exp. Diabetes Res. 2009 (2009) 696378.Suche in Google Scholar

19. Hou, Z., Nie, C., Si, Z. and Ma, Y. 'Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α. Diabetes Res. Clin. Pract. 101 (2013) 62-71.Suche in Google Scholar

20. Pieper, G.M. and Siebeneich, W. Diabetes-induced endothelial dysfunction is prevented by long-term treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine. J. Cardiovasc. Pharmacol. 30 (1997) 734-738.10.1097/00005344-199712000-00006Suche in Google Scholar PubMed

21. Nagai, R., Nagai, M., Shimasaki, S., Baynes, J. W. and Fujiwara, Y. Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats. Biochem. Biophys. Res. Commun. 393 (2010) 118-122.10.1016/j.bbrc.2010.01.095Suche in Google Scholar PubMed PubMed Central

22. Ueno, H.M., Urazono, H., Kobayashi, T. Serum albumin forms a lactoferrinlike soluble iron-binding complex in presence of hydrogen carbonate ions. Food Chem. 145 (2014) 90-94.Suche in Google Scholar

23. Fukuzawa, K., Saitoh, Y., Akai, K., Kogure, K., Ueno, S., Tokumura, A., Otagiri, M. and Shibata, A. Antioxidant effect of bovine serum albumin on membrane lipid peroxidation induced by iron chelate and superoxide. Biochim. Biophys. Acta 1668 (2005) 145-155. Suche in Google Scholar